Tag Archives: BRCA mutations

February, 2017

17 February
Lynparza Meets Primary Endpoint in Phase 3 Trial in BRCA-Mutated Metastatic Breast Cancer

WILMINGTON, Del.–(BUSINESS WIRE)–AstraZeneca today announced positive results from its Phase III OlympiAD trial comparing LYNPARZA™ (olaparib) tablets (300mg twice daily) to physician’s choice of a standard of care chemotherapy in the treatment of patients with HER2-negative metastatic breast cancer harboring germline BRCA1 or BRCA2 mutations.1 Patients treated with LYNPARZA showed …
Share

7 October
Clovis to Present Safety and Efficacy Data from its Ovarian Cancer Trial

BOULDER, Colo.–(BUSINESS WIRE)–Clovis Oncology (NASDAQ:CLVS) announced today the oral presentation of the primary efficacy and safety data from its NDA dataset for rucaparib at the 2016 ESMO Congress in Copenhagen. Rucaparib is currently under priority review with FDA for the monotherapy treatment of advanced ovarian cancer in patients with BRCA-mutated tumors …
Share

22 April
Quest Diagnostics Joins French Agency to Launch BRCA Gene Datasharing Initiative

US-based Quest Diagnostics has teamed up with Inserm, the French National Institute of Health and Medical Research institution, to launch an expanded database for BRCA1 and BRCA2 genetic data. The initiative, called BRCA Share, was co-founded by Quest and Inserm to provide scientists and laboratory organizations around the world open …
Share